Kornimate/medical-research-clean huggingface dataset:
effects of characters on parents' perceptions of breakfast cereals

Conditions: Obesity

Summary: purpose: to test how the presence of characters on breakfast cereals affects parents' perceptions and purchase intentions for their children. participants: \~1,000 parents of children ages 2-12 procedures: after completing a screener and reviewing a consent form, participants will complete two unrelated experimental studies. participants will then move on to this study, where they will be randomized into conditions and view three breakfast cereal box images, with or without characters. they will then be asked a series of questions about their children and their perceptions about the breakfast cereals

the use of characters, such as cartoons, is a prolific form of child-oriented marketing and may have particularly persuasive power in children. parents and caregivers - who make most food purchases for children - are also persuaded by child-oriented marketing practices. the purpose of this study is to examine the impact of characters on parents' perceptions and purchase intentions of a breakfast cereal product. setting: this is an online study using qualtrics. recruitment: participants will be recruited by qualtrics panel company, a survey research firm through which participants are recruited voluntarily. informed consent: participants will read a written consent document that includes information about the study's purpose, expectations, and possible risks and benefits. participants will acknowledge that they have read and agreed to the terms by clicking forward. randomization: participants will be randomly assigned to one of two groups: 1.) control (breakfast cereal boxes with no characters) or 2.) characters (breakfast cereal boxes with a brand and at least one licensed character). participants will view three brands (frosted flakes, apple jacks, froot loops). assessment: using an online platform (qualtrics), participants will complete an eligibility screener prior to the first experiment. they will then complete two unrelated experimental studies before beginning the current study. participants will then be randomized into a condition and shown an image of the three cereal brands in random order. after each brand exposure, participants will be asked to respond to a series of questions measuring the following constructs: purchase intentions, perceived healthfulness, and perceived child appeal. after viewing all three brands and answering the aforementioned questions, participants will be queried on their perceptions of their child's perceived food-fussiness. demographic information, such as age, gender, race/ethnicity, education, and income will be gathered at the end of the study.

Eligibility criteria:
inclusion criteria: * age 18 or older * parent or guardian of at least one child between the ages of 2-12 exclusion criteria: * \<18 years old * is not the parent or guardian of a child between the ages of 2-12
a clinical trial to demonstrate the efficacy and safety of cenestin 0.3 mg for the treatment of hot flashes

Conditions: Hot Flashes

Summary: this is a randomized, double-blind study to compare the efficacy and safety of daily doses of cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.

the overall study duration will be approximately 16 weeks. after a screening/baseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or cenestin 0.3mg tablets

Eligibility criteria:
inclusion criteria: * naturally or surgically postmenopausal * at least 12 months since last menses or 6 weeks past surgery * minimum of 7 daily or 50 weekly moderate to severe hot flashes exclusion criteria: * any contraindication to natural or synthetic estrogens

Keywords: menopause vasomotor symptoms
the effect of patient position on the external haller index value among patients with pectus excavatum

Conditions: Pectus Excavatum

Summary: pectus excavatum is the most common anterior chest wall deformity, affecting up to 1:400 of newborns. the current gold standard to quantify the extent of deformity is by calculating the haller index based on a computed tomography (ct)-scan. however, as such scans inescapably imply exposure to ionizing radiation, novel imaging techniques have been investigated. three-dimensional optical surface scanning is a promising new technique to acquire the trunks' three-dimensional (3d) surface topography. based on this 3d scan, one is able to calculate the external haller index that is known to highly correlate with the conventional gold standard haller index that is based on internal measures. both the conventional and external haller index are known to be affected by the respiratory phase in which the scan is acquired, however, what is the effect of patient position on the external haller index, and if affected, how should one correct for this phenomenon? to investigate this, a retrospective single-centre pilot study will be conducted.


Eligibility criteria:
inclusion criteria: * patients that received a three-dimensional optical surface scan to quantify their pectus deformity exclusion criteria: * none

Keywords: three-dimensional optical surface scanning patient position
the safety and effectiveness of 524w91

Conditions: HIV Infections

Summary: to assess the safety and pharmacokinetics of single oral doses of 524w91 administered in hiv-infected patients. to determine the effects of food on bioavailability of 524w91.

patients are randomized to receive six single escalating doses of 524w91 or placebo, with each dose separated by at least a 6-day washout interval. in the time between 2 of the doses, the effect of food on pharmacokinetics will be investigated, with one dose administered in conjunction with a high-fat meal and one dose administered in a fasted state.

Eligibility criteria:
inclusion criteria patients must have: * documented hiv infection. * cd4 count \>= 200 cells/mm3. * no active opportunistic infection. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * malignancy or other condition that would confound study assessment or interfere with ability to complete the study. * malabsorption syndrome or other gastrointestinal dysfunction that might interfere with gastrointestinal absorption. concurrent medication: excluded on the day of each dose: * antiretrovirals. * any prescription or over-the-counter medication. * alcoholic beverages. * coffee, tea, and other xanthine-containing beverages and foods. patients with the following prior conditions are excluded: history of hepatitis, pancreatitis, or cardiomyopathy within the past 5 years. prior medication: excluded: * antiretrovirals within 24 hours prior to each dose. * any prescription or over-the-counter medications within 48 hours prior to each dose. * alcoholic beverages within 48 hours prior to each dose. current alcohol or illicit drug use that may affect patient compliance.

Keywords: acquired immunodeficiency syndrome aids-related complex antiviral agents
hepatocellular carcinoma in hiv-infected patients

Conditions: Hepatocellular Carcinoma; HIV; Chronic Hepatitis C; Hepatitis B Virus; Liver Cirrhosis

Summary: observational study. all hiv-infected patients who have been diagnosed of hepatocellular carcinoma (hcc), following the american association for the study of liver diseases (aasld) criteria, in the participant centers are included. epidemiological, clinical and laboratory data are collected. the clinical and epidemiological characteristics of hcc cases will be analyzed. the efficacy and outcomes after modalities of hcc therapy will be assessed. mortality and its predictors will be also assessed. in those cases infected by hepatitis c virus (hcv), the impact of hcv therapy on outcomes will be analysed.


Eligibility criteria:
inclusion criteria: * hiv infection * diagnosis of hepatocellular carcinoma according to american association for the study of liver diseases (aasld) criteria exclusion criteria: * none
effects of prismatic spectacle lenses on symptoms of dizziness, headache and anxiety as caused by vertical heterophoria

Conditions: Binocular Dysfunction; Vertical Heterophoria; Vision, Binocular; Vision Disparity

Summary: the purpose of this study is to demonstrate whether, in patients diagnosed with vertical heterophoria, the symptoms of dizziness, headache and / or anxiety are reduced or eliminated when a kind of correction called vertical prism is added to the patient's normal eye glass prescription. the experiment will involve giving the patient two pairs of glasses (one pair containing the baseline prescription with vertical prism (standard treatment glasses) and the other pair containing the baseline prescription but without vertical prism (placebo glasses)) to demonstrate which pair of glasses is most effective in reducing the symptoms of dizziness, headache and / or anxiety in these patients.


Eligibility criteria:
inclusion criteria: * first time appointment for a patient at designated optometry office for treatment of symptoms associated with vertical heterophoria * must have symptoms of dizziness or headache or both: * dizziness defined as one or more of these: lightheadedness,dizziness, vertigo, feeling off-balance, lack of coordination / "clumsy", unsteadiness while walking or drifting / veering to one side while walking, motion sickness * headache defined as one or more of these: pain anywhere in the head,posterior neck / upper trapezius (upper back), face, and in and / or around the eyes * duration of symptoms greater than 4 months * evaluated for these symptoms previously by at least 1 other doctor (general practice, family practice, internal medicine, neurology, ent, emergency medicine, pediatrics, pm\&r, ophthalmology). * age \>14 * the patient (or their representative) must be able and willing to fill out extra paperwork * all patients to be seen by same optometrist for all visits * must be willing to wear glasses. * the patient (or their representative) must be able to sign informed consent * must have a driver for follow up visits where control and treatment glasses are dispensed, and when washout period is initiated * must have a driver for follow up visits where control and treatment glasses are dispensed, and when washout period is initiated * must have previous negative neuroimaging (hct or mri) that was ordered to assess for headache and / or dizziness exclusion criteria: * previous diagnosis of strabismus, vertical heterotropia, cn 3, 4 or 6 palsy, "lazy eye" * previous eye injury or eye operation (including rk and lasik) * diagnosis of glaucoma * diagnosis of cataracts * diagnosis of proptosis * previous c-spine surgery / fusion * previous rx contains prismatic correction * \>18 pd of exophoria * \> 4 pd of vertical heterophoria on initial exam

Keywords: vision, binocular vision disparity headache dizziness anxiety neck pain learning disorders asthenopia motion sickness depth perception gait disorder diplopia photophobia agoraphobia panic disorder
safety and efficacy of bivalirudin during short-term intervention of non-infarction related artery after ppci of stemi

Conditions: STEMI With Multivessel Coronary Disease

Summary: this is a randomized, open label, cohort study, in which a total of 100 patients will be enrolled and randomly assigned to receive bivalirudin or heparin in a 1:1 ratio during short-term intervention of non-infarction related artery for acute st-segment elevation myocardial infarction after emergency percutaneous coronary intervention. nace, mace, any type of barc bleeding, stent thrombosis will be evaluated in 30 days and 6 months after recruitment.

the 2017 guideline gives a class iia recommendation ('should be considered') for complete revascularisation in patients presenting with stemi and multivessel disease, which is approximately 50% of the stemi population. staged multivessel pci during hospitalization (3-5 days after ppci) is common in contemporary practice. patients undergoing primary pci should receive enhanced antithrombotic therapy, includes dapt and and parenteral anticoagulant, which caused an increased bleeding risk. in addition, repeated use of heparin in a short time may increase the incidence of hit. direct thrombin inhibitor bivalirudin, demonstrated a reduced risk of bleeding and an overall favorable profile including reduced nace. this is a randomized, open label, cohort study, which is aimed to investigate the safety and efficacy of bivalirudin during short-term intervention of non-infarction related artery for acute st-segment elevation myocardial infarction after emergency percutaneous coronary intervention.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * acute stemi (including patients within 12 h of symptom onset, or 24-48 h with recurrent or ongoing chest pain chest pain, persistent st-segment elevation or new left bundle branch block. * staged intervention of non-infarction related artery within 5 days after ppci during hospitalization. * signed informed consent. exclusion criteria: * cardiogenic shock. * received thrombolytic therapy or used any anticoagulant drugs within 48 hours before randomized. * active bleeding, recent bleeding events or bleeding tendency. * history of surgery in the last 1 month. * suspicious symptoms of aortic dissection, pericarditis and endocarditis. * blood pressure \> 180/110 mmhg. * hemoglobin \< 100 g/l, platelet count \<100×10(9)/l, transaminase 3 times upper limit of normality or creatinine clearance \<30ml/min. * history of heparin-induced thrombocytopenia. * allergic to any research drug or device. * pregnancy or lactation. * any condition that makes the patient unsuitable for pci or may interfere with the study. * patient disagrees or fails to sign the written informed consent.
this trial evaluates safety, pharmacokinetic profile and anti-viral response of bi 207127 and bi 201335 for patients with chronic hepatitis c

Conditions: Hepatitis C, Chronic

Summary: the objective of this trial is to investigate tolerability, safety, pharmacokinetics and antiviral activity of bi 207127 na in combination with bi 201335 na and ribavirin for 8 weeks in japanese treatment-naive patients with chronic gt-1 hcv infection.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c, diagnosed by positive anti-hepatitis c virus(hcv) antibodies and detected hcv ribonucleic acid(rna) at screening in addition to: 1. positive anti-hcv antibodies or detected hcv rna at least 6 months prior to screening; or, 2. liver biopsy consistent with chronic hcv infection. * hcv infection of genotype 1 confirmed by genotypic testing at screening * therapy-naïve to interferon, pegylated interferon, ribavirin or any antiviral / immunomodulatory drug for acute or chronic hcv infection. * plasma hcv rna = 100,000 iu/ml at screening exclusion criteria: * hepatitis c infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening * human immunodeficiency virus (hiv) co-infection * decompensated liver disease, or history of decompensated liver disease * body weight \ 125 kg at screening * hemoglobin \<12.0g/dl for women and \<13.0g/dl for men at screening * white blood cell count \<3000 cells/mm3 at screening * absolute neutrophil count \< 1,500 cells/mm3 at screening * platelet count \< 90,000 /mm3 at screening * serum creatinine \> 1.5xupper limit of normal range(uln) or creatinine clearance =50 ml/min at screening
efficiency of patient blood management protocol in gynecological surgery department (periopesgyneco)

Conditions: Anemia

Summary: perioperative anemia is associated with higher risk of red blood cell transfusion, higher rates of morbimortality and lower quality of postoperative recovery. in a context of focussing on higher quality management and improved recovery after surgery, development of patient blood management has increased. this study aim to assess pbm protocole in a postoperative context of gynaecological surgery, by comparing indicators at two time periods: 2 and 8 months after establishment of pbm protocol.


Eligibility criteria:
inclusion criteria: * age \> 18 years * being hospitalised for planned hysterectomy or cancer related ovariectomy exclusion criteria: * less than 18 years * non french speaker * being under a legal individual protection measure * not being able to consent * being opposed to data collection

Keywords: anemia perioperative period post operative recovery patient blood management
clinical and radiological outcomes of medacta shoulder system (be)

Conditions: Primary Osteoarthritis; Secondary Osteoarthritis; Rotator Cuff Tear Arthropathy; Rheumatoid Arthritis Shoulder; Avascular Necrosis; Fracture; Revision of Shoulder Arthroplasty

Summary: this is a post-market surveillance study on medacta shoulder system


Eligibility criteria:
inclusion criteria: * patients older than 18 years * patient with one of the following diagnosis: 1. primary osteoarthritis 2. secondary osteoarthritis 3. cuff tear arthropathy; insufficient rotator cuff 4. acute fracture (\<21d) 5. rheumatoid or inflammatory arthritis 6. avascular necrosis 7. other posttraumatic condition 8. revision of shoulder arthroplasty exclusion criteria: * patients with malignant diseases (at the time of surgery) * patients with proven or suspect infections (at the time of surgery) * patients with functional deficits other than dysfunction of the shoulder (at the time of surgery) * patients with known incompatibility or allergy to products materials (at the time of surgery)
lung ventilation and perfusion in different phenotypes of chronic critical illness with prolonged mechanical ventilation

Conditions: Prolonged Mechanical Ventilation

Summary: this project will conduct a series of analysis of physiological and clinical data on tracheostomy patients who receive prolonged mechanical ventilation, hoping to find out the different manifestations of patients through the investigation by a variety of physiologic measurements, so as to understand whether different types of patients phenotype to derive different clinical strategies for liberation of the mechanical ventilator.


Eligibility criteria:
inclusion criteria: * patients with at least 10 days of mechanical ventilation at the intensive care unit of national taiwan university hospital and transferred to the respiratory care center of national taiwan university hospital for weaning training * patients who have undergone tracheostomy and still have a tracheotomy tube * are at least 20 years old * stable respiratory condition with inspired oxygen fraction not exceeding 50% exclusion criteria: * hemodynamic instability or continuous use of vasopressors * pregnancy

Keywords: ventilation mechanical ventilation weaning oxygen uptake
turnip consumption and qigong exercise program on weight loss

Conditions: Obesity, Adolescent

Summary: obesity and weight-related issues are prevalent concerns affecting individuals worldwide, with particular significance among the younger demographic, such as female students. as lifestyles evolve and dietary habits play a pivotal role in overall well-being, exploring innovative approaches to weight management becomes imperative. thus, obesity is a huge public health importance with economic emotional and social consequences.

obesity is an epidemic causing serious health consequences, including diabetes, dyslipidemia, and hypertension. obesity in adolescents can cause chronic brain hypoxia and affect learning. weight loss occurs when energy intake is less than energy expenditure, and achieving an energy deficit remains the main dietary target. the evidence for the specific impact of vegetables is qualified. recently, there has been much scientific interest and debate on the potential link between dairy consumption and body weight regulation. the idea of turnip consumption and qigong exercise includes a broad variety of subjects. vegetables are high in water and fiber and low in energy density, so their consumption is suggested to prevent obesity. moreover, traditional chinese exercises are an ancient way of exercise and fitness, which have been reported to have unique advantages in the treatment of obesity.

Eligibility criteria:
inclusion criteria: * aged from 10 to 12 years * free from any chronic diseases * accept to participate exclusion criteria: * have any digestive problems * unable to communicate or participate

Keywords: obesity qigong exercise turnip consumption weight loss
acute eosinophilic myocarditis international registry

Conditions: Myocarditis

Summary: retrospective collection of clinical, histological, imaging data regarding patients with acute histologically-proven eosinophilic myocarditis.

eosinophilic myocarditis (em) is an acute life-threatening inflammatory disease of the heart. we collect clinical, histologic, laboratory, diagnostic and imaging data regarding acute em with a histological diagnosis and symptoms onset within 30 days from first medical contact from hospitals around the world. the main objective is to investigate and describe clinical presentation, main systemic conditions associated and outcomes of the first series of patients with acute myocarditis and histological evidence of eosinophilic infiltration within myocardium.

Eligibility criteria:
patients with histological diagnosis gained during an hospitalization within 30 days from symptoms onset.

Keywords: eosinophilic myocarditis endomyocardial biopsy
immunotherapy: care and prevention of infectious and tumoral diseases (immunohub)

Conditions: SARS CoV-2; Liver Tumours

Summary: the project comprises two research lines. in the line 1, human monoclonal antibodies toward sars-cov-2 will be generate and characterized by in vitro functional tests. in the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.


Eligibility criteria:
inclusion criteria: line 1: - age \>18 at time of signing informed consent form * signed informed consent form line 2: - primery liver tumor * age \>18 at time of signing informed consent form * signed informed consent form exclusion criteria: line 1: - active or history of neoplastic malignancy * active autoimmune disease ongoing treatment with immunosuppressive therapy * evidence of positive hiv, hcv, hbv test * diabetes * failure to sign informed consent form line 2: - concomitant diseases with life expectancy of less than 12 months * chronic autoimmune or inflammatory diseases * treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-vegf therapies * other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse * hiv infection * failure to sign informed consent form